More than three-quarters of lupus patients taking obinutuzumab (Gazvya) had a significant improvement in their symptoms after a year on the drug, researchers reported March 6 in The New England ...

Phase 3 trial data show that obinutuzumab significantly reduces disease activity in very active extrarenal lupus.

Higher rates of mortality seen among patients with systemic lupus erythematosus, with disparities by sex, race and ethnicity, and region.

Please provide your email address to receive an email when new articles are posted on . Despite declining mortality rates, racial, sex and geographic disparities persist for patients with lupus. Early ...